Estrella Immunopharma (Estrella Immunopharma) Dividend Payout Ratio : 0.00 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Dividend Payout Ratio?

Estrella Immunopharma's dividend payout ratio for the months ended in Mar. 2024 was 0.00.

The historical rank and industry rank for Estrella Immunopharma's Dividend Payout Ratio or its related term are showing as below:

ESLAW's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-08), the Dividend Yield % of Estrella Immunopharma is 0.00%.

Estrella Immunopharma's Dividends per Share for the months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Estrella Immunopharma Dividend Payout Ratio Historical Data

The historical data trend for Estrella Immunopharma's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Dividend Payout Ratio Chart

Estrella Immunopharma Annual Data

Trend

Jun21

Dividend Payout Ratio

Estrella Immunopharma Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Dividend Payout Ratio	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Estrella Immunopharma's Dividend Payout Ratio

For the Biotechnology subindustry, Estrella Immunopharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Estrella Immunopharma's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's Dividend Payout Ratio falls into.

Estrella Immunopharma Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Estrella Immunopharma's Dividend Payout Ratio for the fiscal year that ended in Jun. 2021 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Jun. 2021 )	/	EPS without NRI (A: Jun. 2021 )
	=	0	/	0
	=	N/A

Estrella Immunopharma's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	0
	=	N/A

Estrella Immunopharma (NAS:ESLAW) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Estrella Immunopharma Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma (Estrella Immunopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLAW) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

ESLA:USA

Address

5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608

Website

https://www.estrellabio.com

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines